| ObjectiveThe study combined the traditional Chinese medicine compound preparation Jiakangling tablets with Mathimazole to treat Graves’ Disease,observing the variation of clinical effect,thyroid auto-antibodies and the inflammatory factors Interleukin-10(IL-10),Interleukin-18(IL-18)before and after therapy.To investigate the effect of thyroid immune function and inflammatory maker levels after Jiakangling tablets on treating Graves’Disease.Methods①According to the method of randomized controlled clinical trial,we filtered 70 patients from the endocrinology department of Foshan Hospital Of TCM from February 2019 to October 2019 via the inclusion and exclusion rules.They were not only newly diagnosed with Graves’ Disease,but also with yin deficiency and yang hyperactivity.They were divided into two groups randomly,consist of the treatment group(Jiakangling tablets combined with Mathimazole)34 cases(post-shedding 1 case),the control group(Mathimazole)33 cases(post-shedding 2 cases),and the course of treatment was 12 weeks.In addition,34 cases of healthy people were selected as the reference index without treating,who matched the age of the same term.②Detecting the serum of free triiodothyronine(FT3),free thyroxine(FT4),thyroid-stimulating hormone(TSH),TSH receptor antibody(TRAb),anti-thyroid peroxidase antibody(TPOAb),anti-thyroglobulin antibody(TgAb)and IL-10,IL-18 and observing the change of their levels before and after therapy in the two groups.③SPSS 20.0 was used to analyze the data of results statistical.Results1.The age,sex,FPG,WBC,TC,TG,Cr,ALT levels among all participants were not significant statistically(P>0.05).2.Compared with the healthy group,the levels of serum FT3,FT4,TRAb,TPOAb,TgAb,IL-18 in Graves’ Disease group were higher,the levels of serum TSH,IL-10 were lower,the difference was significant statistically(P<0.01).3.Compared with control group,the levels of serum FT3,FT4,TSH,TRAb,TPOAb,TgAb,IL-10,IL-18 in treatment group before therapy were not significant statistically(P>0.05).4.After 12 weeks of treatment,the levels of serum FT3,FT4,TPOAb,TgAb were decreased and the levels of serum TSH were increased in both groups,but the difference were not significant statistically between treatment group and control group(P>0.05).The levels of serum TRAb were decreased in both group(P<0.01),compared with control group,the levels of serum TRAb were significantly lower in treatment group(P<0.01).The levels of serum IL-18 were decreased in both group(P<0.01),compared with control group,the levels of serum IL-18 were significantly lower in treatment group(P<0.05).The levels of serum IL-10 were increased in both group(P<0.01),compared with control group,the levels of serum IL-10 were significantly higher in treatment group(P<0.05).The TCM syndrome scores were decreased in both group(P<0.01),compared with control group,the TCM syndrome scores were significantly lower in treatment group(P<0.01).5.In the effect of TCM clinical syndrome,the total effective rate of the treatment group was significantly higher than control group(P<0.05).Compared with control group,_there were less adverse reactions in treatment group(P<0.05)·Conclusion1.The levels of serum TRAb,TPOAb,TgAb in Graves’ Disease group obviously higher,indicating that there exists an immune disorder in Graves’ Disease group.The levels of serum IL-18 were higher while IL-10 were lower in Graves Disease patients,_indicating that there is an inflammatory responses in the body.2.Jiakangling tablets with Mathimazole has a good therapeutic effect on Graves’ Disease with yin deficiency and yang hyperactivity and less adverse reactions.3.After therapy,the treatment group was more advantageous in reducing the levels of serum TRAb,suggesting that Jiakangling tablets combined with Methimazole could significantly improve the immune balance in Graves’disease.4.After therapy,the levels of serum IL-18 were lower and IL-10 were higher in the treatment group,indicating that the combination of Jiakangling tablets and Methimazole could reduce the inflammatory state of Graves’disease. |